Crossmark

Mid-term impact of underfilling and overfilling of the SAPIEN 3 balloon-expandable transcatheter aortic valve implantation on mortality and valve function

Crossref DOI link: https://doi.org/10.1007/s00380-022-02109-9

Published Online: 2022-06-18

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ishizu, Kenichi https://orcid.org/0000-0003-3551-5525
Shirai, Shinichi

Tashiro, Hiroaki

Kitano, Kazuki

Tabata, Hiroyuki

Morofuji, Toru

Nakamura, Miho

Murakami, Naoto

Morinaga, Takashi

Hayashi, Masaomi

Isotani, Akihiro

Arai, Yoshio

Ohno, Nobuhisa

Kakumoto, Shinichi

Ando, Kenji
License Information

Text and Data Mining valid from 2022-06-18

Version of Record valid from 2022-06-18
More Information

Article History

Received: 25 January 2022

Accepted: 25 May 2022

First Online: 18 June 2022

Declarations

:

: Shinichi Shirai, MD, is the proctor of transfemoral-TAVR for Edwards Lifesciences and Medtronic. Yoshio Arai, MD, PhD, is the proctor of transapical-TAVR for Edwards Lifesciences. The other authors have no potential conflict of interest relevant to this article. The other authors have no conflicts of interest to declare.

: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Kokura Memorial Hospital approved this study.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below